[
    [
        {
            "time": "2021-08-29",
            "original_text": "智飞生物上半年盈利近55亿元 同比大增265%",
            "features": {
                "keywords": [
                    "智飞生物",
                    "盈利",
                    "同比大增",
                    "265%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物上半年盈利近55亿元 同比大增265%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "智飞生物(300122.SZ)上半年归母净利润同比增265%至54.91亿元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "归母净利润",
                    "同比增",
                    "54.91亿元"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物(300122.SZ)上半年归母净利润同比增265%至54.91亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "智飞生物2021年中报净利同比增长265% 上半年研发投入近8亿",
            "features": {
                "keywords": [
                    "智飞生物",
                    "中报",
                    "净利增长",
                    "研发投入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物2021年中报净利同比增长265% 上半年研发投入近8亿",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "智飞生物：上半年净利润54.91亿元 同比增265%",
            "features": {
                "keywords": [
                    "智飞生物",
                    "净利润",
                    "同比增",
                    "54.91亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：上半年净利润54.91亿元 同比增265%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "医药行业周报：疫情常态化 疫苗产业链值得长期关注",
            "features": {
                "keywords": [
                    "医药行业",
                    "疫情常态化",
                    "疫苗产业链",
                    "长期关注"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：疫情常态化 疫苗产业链值得长期关注",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "智飞生物：上半年净利润同比增长264.94%",
            "features": {
                "keywords": [
                    "智飞生物",
                    "净利润",
                    "同比增长",
                    "264.94%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：上半年净利润同比增长264.94%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "中泰证券维持智飞生物买入评级：重组新冠疫苗三期数据具备全球竞争力，看好下半年出口加速",
            "features": {
                "keywords": [
                    "中泰证券",
                    "智飞生物",
                    "买入评级",
                    "重组新冠疫苗",
                    "全球竞争力",
                    "出口加速"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持智飞生物买入评级：重组新冠疫苗三期数据具备全球竞争力，看好下半年出口加速",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "新冠疫苗重大利好：智飞生物“重组蛋白”路径产品Ⅲ期临床即将收官 Delta变异株防护率77.54%",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "智飞生物",
                    "重组蛋白",
                    "Ⅲ期临床",
                    "Delta变异株",
                    "防护率77.54%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠疫苗重大利好：智飞生物“重组蛋白”路径产品Ⅲ期临床即将收官 Delta变异株防护率77.54%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        }
    ]
]